Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

Inclusion Criteria: * Patient must have been between the ages of 4 and 11 years at the time of entry into the double blind study. * Patients must meet diagnostic criteria for FASD. * Patient must, at entry into doubleblind study, have met DSM-IV criteria for ADHD, any subtype. And must have an ADHDRS-IV score of \> or + 90% for age and gender on either subtest or total score for children above 5 years of age. * Patients will continue atomoxetine/placebo until entry nto this study. * History and physical exam must reveal no clinically significant abnormalities that would preclude safe participation in the study. * Patients must be able to swallow capsules. * Patients must be of a sufficient mental age (3 yrs) to participate in the study. * Patients and parents must be able to communicate effectively with the investigator and coordinator and be judged reliable to keep appointments and participate in data collection. * Teacher must agree to cooperate with the study. Exclusion Criteria: * Have received an investigational medication other than atomoxetine in the previous 30 days. * Have significant current medical conditions that could be exacerbated or compromised by atomoxetine. * Have used MAOIs within one month prior to visit 1. * Patients with hypertension. * Patients with a previous diagnosis of bipolar disorder, psychosis, or autism spectrum disorder. * Patients taking anticonvulsants for seizure control. * Patients taking another psychotropic medication or health food supplements purported to have central nervous system activity within 5 half-lives of visit 1. * Patients with Tourette Disorder or any other neurological condition that would interfere with their ability to receive treatment or comply with monitoring. * Pubertal girls.